Weight loss translates to investor profits. Just look at Eli Lilly and Novo Nordisk. Both stocks have skyrocketed thanks largely to their obesity drugs, with Lilly's share price more than quadrupling and Novo's shares more than tripling over the last three years. Meanwhile, Pfizer's (NYSE: PFE) fortunes ...
motleyfoolusx:pfe
Image source: The Motley Fool. Pfizer (NYSE: PFE) Q1 2024 Earnings Call May 01, 2024, 10:00 a.m. ET Operator Continue reading
motleyfoolusx:pfe
Pfizer (NYSE: PFE) stock got a very effective shot in the arm on Wednesday. This was supplied by its latest earnings release, which saw the storied pharmaceutical company notch double beats on analyst estimates and provide encouraging guidance. The company's share price ended the day more than 6% higher, ...
motleyfoolusx:pfe
Shares of Pfizer Inc. (NYSE: PFE) gained over 5% on Wednesday following the company’s announcement of its first quarter 2024 earnings results. Although the top and bottom line numbers decreased from the prior year, they surpassed analysts’ projections. The pharma giant also raised its adjusted EPS guidance ...
alphastreetusx:pfe
Pfizer Inc. (NYSE: PFE) reported first quarter 2024 earnings results today. Revenues decreased 20% year-over-year to $14.8 billion. Reported net income declined 44% to $3.1 billion, or $0.55 per share, compared to last year. Adjusted EPS fell 33% to $0.82. Revenue and earnings beat estimates, allowing ...
alphastreetusx:pfe
Earnings season is officially here. As per usual, there have already been epic sell-offs and run-ups across well-known names. However, long-term investors know that the best way to view a quarterly earnings report is within the context of an investment thesis rather than the market's knee-jerk reaction ...
motleyfoolusx:neeusx:msftusx:fvrrusx:hdusx:pfe
"If you don't find a way to make money while you sleep, you will work until you die." That's a quote from billionaire investor Warren Buffett which emphasizes the importance of making your money work for you. By generating income without having to work, you improve your financial position and potentially ...
motleyfoolusx:pfeusx:tusx:bns
If you had bought $1,000 worth of Pfizer (NYSE: PFE) shares five years ago, how much would that be worth today? The answer will strike you as terrific or terrible: $840. That answer will be terrible if you did buy into Pfizer then as it reflects a loss, not a gain -- of about 16% -- yikes! Annualized, ...
motleyfoolusx:pfe
With the new financial year under way, Iâve been looking for stocks to buy. And Iâve got things moving with a pair of dividend shares look like a bargain to me. Neither is a UK stock, which is unusual for me. But a delay to interest rate cuts across the Atlantic has created some opportunities in ...
motleyfoolukusx:pfeusx:o
Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to equally outsized windfalls. But for investors, it could still be a great pickup once a few of the loftier expectations ...
motleyfoolusx:pfe
Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have resulted in a lot of investors simply taking a pass on this top healthcare stock. But could that be a mistake, ...
motleyfoolusx:pfe
Later this year, the Federal Reserve is projected to begin reducing interest rates. While the exact number of rate cuts is still uncertain, this regulatory action is expected to stimulate a surge in high-yield dividend stocks, primarily because fund managers tend to aggressively purchase high-yield dividend ...
motleyfoolusx:pfeusx:t
Three Motley Fool contributors have dividends on their minds as the second quarter of 2024 begins. And they think they've found some no-brainer dividend stocks to buy in April. Here's why they like AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). Keith Speights (AbbVie): What's ...
motleyfoolusx:gildusx:pfeusx:abbv
No pair of companies dominated the COVID-19 vaccine market quite like Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). Both saw their revenue and earnings skyrocket, along with their share prices, as governments rushed to buy millions of doses of their respective vaccines. However, this tailwind came to ...
motleyfoolusx:mrnausx:pfe
Price matters. That's true whether we're talking about cars, houses, laptops, or anything else -- including stocks. Three Motley Fool contributors had price in mind when choosing Axsome Therapeutics (NASDAQ: AXSM), CRISPR Therapeutics (NASDAQ: CRSP), and Pfizer (NYSE: PFE) as top picks for investors ...
motleyfoolusx:pfeusx:crspusx:axsm
